Serum biomarkers in SSc-ILD: association with presence, severity and prognosis
C. Stock (London, United Kingdom), A. De Lauretis (London, United Kingdom), D. Visca (London, United Kingdom), C. Daccord (London, United Kingdom), M. Kokosi (London, United Kingdom), V. Alfieri (London, United Kingdom), V. Kouranos (London, United Kingdom), G. Margaritopoulos (London, United Kingdom), P. George (London, United Kingdom), P. Molyneaux (London, United Kingdom), F. Chua (London, United Kingdom), T. Maher (London, United Kingdom), V. Ong (London, United Kingdom), D. Abraham (London, United Kingdom), C. Denton (London, United Kingdom), A. Wells (London, United Kingdom), E. Renzoni (London, United Kingdom)
Source: International Congress 2019 – From biomarkers to treatment of immune-mediated interstitial lung disease: what’s new?
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Stock (London, United Kingdom), A. De Lauretis (London, United Kingdom), D. Visca (London, United Kingdom), C. Daccord (London, United Kingdom), M. Kokosi (London, United Kingdom), V. Alfieri (London, United Kingdom), V. Kouranos (London, United Kingdom), G. Margaritopoulos (London, United Kingdom), P. George (London, United Kingdom), P. Molyneaux (London, United Kingdom), F. Chua (London, United Kingdom), T. Maher (London, United Kingdom), V. Ong (London, United Kingdom), D. Abraham (London, United Kingdom), C. Denton (London, United Kingdom), A. Wells (London, United Kingdom), E. Renzoni (London, United Kingdom). Serum biomarkers in SSc-ILD: association with presence, severity and prognosis. 5198
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: